STM2457
Based on 113 publication(s) in Google Scholar
STM2457 is a first-in-class, highly potent, selective and orally active METTL3 inhibitor with an IC50 of 16.9 nM. STM2457 can be used for the research of acute myeloid leukaemia (AML).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.55%
- No. CAS: 2499663-01-1
- Fòrmula: C25H28N6O2
- Peso molecular:444.53
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Orally Active Compound Library
HY-L061
-
Chemical Probe Library
HY-L063
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Methylation Compound Library
HY-L203
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
-
Epigenetics Compound Library Mini
HY-L005M
-
Apoptosis Compound Library
HY-L003
-
Epigenetics Compound Library
HY-L005
-
Anti-Cancer Compound Library
HY-L025
Publications Citing Use of MedChemExpress (MCE) STM2457
More- Cell. 2025 Feb 20;188(4):998-1018.e26. [Abstract]
- Nat Biotechnol. 2024 Sep;42(9):1417-1428. [Abstract]
- Nat Biotechnol. 2023 Mar;41(3):355-366. [Abstract]
- Gastroenterology. 2022 Oct;163(4):891-907. [Abstract]
- Cancer Commun (Lond). 2025 Nov;45(11):1583-1610. [Abstract]
- Cancer Commun (Lond). 2022 Apr;42(4):327-344. [Abstract]
- Nat Methods. 2025 Jun;22(6):1226-1236. [Abstract]
- Nat Genet. 2023 Aug;55(8):1324-1335. [Abstract]
- Bioact Mater. 2024 Oct 22:44:236-255. [Abstract]
- Cell Stem Cell. 2025 Oct 29:S1934-5909(25)00371-6. [Abstract]
- Autophagy. 2026 Jun 26:1-17. [Abstract]
- Nat Commun. 2026 Feb 12;17(1):1214. [Abstract]
- Nat Commun. 2025 Jun 6;16(1):5251. [Abstract]
- Nat Commun. 2024 Nov 15;15(1):9890. [Abstract]
- Nat Commun. 2024 Jun 26;15(1):5410. [Abstract]
- Nat Commun. 2024 Feb 14;15(1):1353. [Abstract]
- Redox Biol. 2024 Aug:74:103194. [Abstract]
- Nucleic Acids Res. 2026 Mar 19;54(6):gkag220. [Abstract]
- Nucleic Acids Res. 2024 Jul 8;52(12):7261-7278. [Abstract]
- J Exp Clin Cancer Res. 2023 Mar 17;42(1):65. [Abstract]
- Adv Sci (Weinh). 2025 Mar;12(11):e2409419. [Abstract]
- Cell Rep Med. 2023 Aug 15;4(8):101144. [Abstract]
- Sci Adv. 2024 Oct 4;10(40):eadp5332. [Abstract]
- Cardiovasc Res. 2025 May 6;121(4):568-584. [Abstract]
- Cell Death Dis. 2025 Dec 8;16(1):880. [Abstract]
- Cell Death Dis. 2025 Oct 7;16(1):708. [Abstract]
- Environ Sci Technol. 2025 Feb 18;59(6):2974-2986. [Abstract]
- Cell Death Dis. 2024 Jun 17;15(6):422. [Abstract]
- Blood Cancer Discov. 2023 May 1;4(3):228-245. [Abstract]
- Cell Commun Signal. 2025 Mar 8;23(1):126. [Abstract]
- Cell Commun Signal. 2023 May 25;21(1):121. [Abstract]
- Mol Ther. 2025 Dec 3;33(12):6146-6159. [Abstract]
- Phytomedicine. 2024 Dec:135:156002. [Abstract]
- J Pharm Anal. 2023 Jun;13(6):625-639. [Abstract]
- J Hazard Mater. 2023 Sep 15:458:131891. [Abstract]
- Cell Death Discov. 2025 Mar 15;11(1):104. [Abstract]
- J Orthop Translat. 2026 Feb 18:57:101056. [Abstract]
- J Transl Med. 2024 Oct 8;22(1):914. [Abstract]
- Dev Cell. 2025 Nov 20:S1534-5807(25)00666-5. [Abstract]
- Int J Biol Macromol. 2025 Dec 3;337(Pt 1):149421. [Abstract]
- EMBO J. 2025 Jul;44(14):4150-4180. [Abstract]
- Mol Med. 2025 Jun 12;31(1):236. [Abstract]
- Free Radic Biol Med. 2025 Mar 1:229:168-182. [Abstract]
- Cell Rep. 2026 Jan 9;45(1):116828. [Abstract]
- Cell Rep. 2025 Jun 18;44(7):115871. [Abstract]
- Cell Rep. 2024 Jun 14;43(6):114369. [Abstract]
- Cell Rep. 2022 Jul 19;40(3):111107. [Abstract]
- Cell Prolif. 2024 Dec;57(12):e13707. [Abstract]
- Virulence. 2026 Dec;17(1):2645908. [Abstract]
- Discov Nano. 2026 May 28;21(1):223. [Abstract]
- Ecotoxicol Environ Saf. 2024 Sep 15:283:116803. [Abstract]
- Biochem Pharmacol. 2025 Sep:239:117016. [Abstract]
- Biochem Pharmacol. 2025 May:235:116820. [Abstract]
- Cancer Gene Ther. 2026 Mar;33(3):277-288. [Abstract]
- Life Sci. 2023 Nov 15:333:122148. [Abstract]
- Transl Res. 2023 Sep:259:62-71. [Abstract]
- Cells. 2026 Jan;15(3):294.
- Cells. 2026 Feb 4;15(3):294. [Abstract]
- EMBO Rep. 2025 Oct 6. [Abstract]
- Mol Cancer Res. 2025 Mar 3;23(3):190-201. [Abstract]
- Commun Biol. 2025 Mar 26;8(1):496. [Abstract]
- J Gastroenterol. 2026 Jun 11. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Aug;1871(6):167904. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Jun;1871(5):167811. [Abstract]
- PLoS Pathog. 2025 Dec 1;21(12):e1013755. [Abstract]
- Exp Neurol. 2026 Aug:402:115802. [Abstract]
- Neuropharmacology. 2026 Mar 1:285:110777. [Abstract]
- Med Oncol. 2026 Jan 20;43(2):122. [Abstract]
- Cell Signal. 2025 Nov:135:112024. [Abstract]
- Cell Signal. 2025 Mar:127:111533. [Abstract]
- Med Oncol. 2025 Feb 22;42(3):82. [Abstract]
- J Inflamm Res. 2025 Oct 29:18:15033-15047. [Abstract]
- iScience. 2023 Oct 13;26(10):108022. [Abstract]
- Antiviral Res. 2026 Apr:248:106376. [Abstract]
- Biochim Biophys Acta Mol Cell Res. 2025 Jul 24;1872(8):120027. [Abstract]
- FASEB J. 2024 Nov 30;38(22):e70154. [Abstract]
- Biology (Basel). 2023 Jul 14;12(7):1004. [Abstract]
- J Virol. 2025 Jul 22;99(7):e0009825. [Abstract]
- J Virol. 2024 Oct 22;98(10):e0118724. [Abstract]
- J Biol Chem. 2024 May;300(5):107226. [Abstract]
- J Endocrinol Invest. 2025 Jul 9. [Abstract]
- BMC Genomics. 2025 May 20;26(1):509. [Abstract]
- Ren Fail. 2024 Dec;46(1):2343817. [Abstract]
- Pathol Res Pract. 2025 Sep 9:275:156224. [Abstract]
- Genomics. 2025 Oct 13;117(6):111142. [Abstract]
- Reproduction. 2025 Sep 19;170(4):e250251. [Abstract]
- J Leukoc Biol. 2024 Oct 1;116(4):807-815. [Abstract]
- J Cancer. 2024 Jul 16;15(15):4853-4865. [Abstract]
- Mol Biol Rep. 2026 Mar 18;53(1):510. [Abstract]
- PLoS One. 2026 Mar 24;21(3):e0345744. [Abstract]
- Biochemistry. 2022 May 23;61(11):1005-1013. [Abstract]
- Mol Reprod Dev. 2026 May;93(5):e70106. [Abstract]
- Sci Prog. 2025 Jul-Sep;108(3):368504251358007. [Abstract]
- Res Sq. 2026 Apr 27.
- bioRxiv. 2026 Apr 14.
- bioRxiv. 2026 Mar 26.
- bioRxiv. 2026 Mar 18:2026.03.18.712554. [Abstract]
- bioRxiv. 2026 Feb 18:2026.02.16.706212. [Abstract]
- Res Sq. 2025 Dec 19:rs.3.rs-8379573. [Abstract]
- SSRN. 2025 Oct 24.
- bioRxiv. 2025 Sep 12.
- bioRxiv. 2025 Sep 3.
- bioRxiv. 2025 July 17.
- Oncotarget. 2025 May 8:16:291-309. [Abstract]
- bioRxiv. 2025 April 08.
- bioRxiv. 2025 April 29.
- bioRxiv. 2025 Mar 24:2025.03.22.644756. [Abstract]
- bioRxiv. 2025 Jan 31:2025.01.30.635805. [Abstract]
- Res Sq. 2024 Jul 08.
- bioRxiv. 2024 June 25.
- Patent. US20240207446A1.
- Research Square Preprint. 2024 May 3.
- Research Square Print. September 9th, 2022.
Customer Validation & Images
-
RT-PCR
-
WB
-
IF
-
RT-PCR
-
WB
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| EOL1 | IC50 |
1.94 μM
Compound: 3b; STM2457
|
Antiproliferative activity against human EOL1 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay
Antiproliferative activity against human EOL1 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay
|
[PMID: 36692498] |
| HL-60 | IC50 |
10.3 μM
Compound: 3b; STM2457
|
Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay
Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay
|
[PMID: 36692498] |
| Huh-7 | GI50 |
0.6 μM
Compound: 8; STM2457
|
Growth inhibition of human Huh-7 cells
Growth inhibition of human Huh-7 cells
|
[PMID: 38805939] |
| Kasumi 1 | IC50 |
0.7 μM
Compound: 3b; STM2457
|
Antiproliferative activity against human Kasumi 1 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay
Antiproliferative activity against human Kasumi 1 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay
|
[PMID: 36692498] |
| MOLM-13 | IC50 |
1.04 μM
Compound: 3b; STM2457
|
Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay
Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay
|
[PMID: 36692498] |
| NCI-H1975 | IC50 |
65.8 μM
Compound: STM2457
|
Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 39291017] |
| NOMO-1 | IC50 |
0.6 μM
Compound: 3b; STM2457
|
Antiproliferative activity against human NOMO-1 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay
Antiproliferative activity against human NOMO-1 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay
|
[PMID: 36692498] |
| OCI-AML2 | IC50 |
1.78 μM
Compound: 3b; STM2457
|
Antiproliferative activity against human OCI-AML2 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay
Antiproliferative activity against human OCI-AML2 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay
|
[PMID: 36692498] |
| OCI-AML-3 | IC50 |
3.2 μM
Compound: 3b; STM2457
|
Antiproliferative activity against human OCI-AML-3 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay
Antiproliferative activity against human OCI-AML-3 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay
|
[PMID: 36692498] |
| PC-9 | IC50 |
69.15 μM
Compound: STM2457
|
Antiproliferative activity against human PC-9 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human PC-9 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 39291017] |
| THP-1 | IC50 |
1.5 μM
Compound: 3b; STM2457
|
Antiproliferative activity against human THP-1 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay
Antiproliferative activity against human THP-1 cells assessed as inhibition of cell proliferation and measured after 7 days by CellTiter-Glo assay
|
[PMID: 36692498] |
STM2457 (Compound 72) inhibits MOLM13 cells proliferation with an IC50 of 8.699 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 2499663-01-1
-
Appearance Solid
-
Peso molecular 444.53
-
Fòrmula C25H28N6O2
-
Color White to yellow
-
SMILES
O=C(C(N=C1N2C=CC=C1)=CC2=O)NCC3=CN4C=C(CNCC5CCCCC5)C=CC4=N3
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (113)
-
Journal Impact Factor
-
Most Recent
-
Cell
Fine-tuning of gene expression through the Mettl3-Mettl14-Dnmt1 axis controls ESC differentiation. [Abstract]2025 Feb 20;188(4):998-1018.e26. PMID: 39826545 -
Nat Biotechnol
2024 Sep;42(9):1417-1428. PMID: 38168988 -
Nat Biotechnol
Absolute quantification of single-base m6A methylation in the mammalian transcriptome using GLORI. [Abstract]2023 Mar;41(3):355-366. PMID: 36302990 -
Gastroenterology
METTL3 Inhibits Antitumor Immunity by Targeting m6A-BHLHE41-CXCL1/CXCR2 Axis to Promote Colorectal Cancer. [Abstract]2022 Oct;163(4):891-907. PMID: 35700773 -
Cancer Commun (Lond)
Intranuclear paraspeckle-circular RNA TACC3 assembly forms RNA-DNA hybrids to facilitate MASH-related hepatocellular carcinoma growth in an m6A-dependent manner. [Abstract]2025 Nov;45(11):1583-1610. PMID: 41103024 -
Cancer Commun (Lond)
m6 A-mediated regulation of PBX1-GCH1 axis promotes gastric cancer proliferation and metastasis by elevating tetrahydrobiopterin levels. [Abstract]2022 Apr;42(4):327-344. PMID: 35261206
STM2457 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2022 Apr;42(4):327-344. [Abstract]
The protein levels of PBX1 and GCH1 decreased in AGS cells treated with STM2457 (10 μM; 0–48 h), while METTL3 levels showed no change (upper panel).
-
Nat Methods
Mild and ultrafast GLORI enables absolute quantification of m6A methylome from low-input samples. [Abstract]2025 Jun;22(6):1226-1236. PMID: 40325216 -
Nat Genet
Crosstalk between RNA m6A and DNA methylation regulates transposable element chromatin activation and cell fate in human pluripotent stem cells. [Abstract]2023 Aug;55(8):1324-1335. PMID: 37474847 -
Bioact Mater
Preventing postsurgical colorectal cancer relapse: A hemostatic hydrogel loaded with METTL3 inhibitor for CAR-NK cell therapy. [Abstract]2024 Oct 22:44:236-255. PMID: 39497707 -
Cell Stem Cell
N6-methyladenosine on L1PA governs the trans-silencing of LTRs and restrains totipotency in naive human embryonic stem cells. [Abstract]2025 Oct 29:S1934-5909(25)00371-6. PMID: 41167193 -
Autophagy
Chaperone-mediated autophagy reprograms heterogeneous subsets of activated macrophages in immune thrombocytopenia. [Abstract]2026 Jun 26:1-17. PMID: 42329073 -
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175 -
Nat Commun
Rewired m6A of promoter antisense RNAs in Alzheimer's disease regulates neuronal genes in 3D nucleome. [Abstract]2025 Jun 6;16(1):5251. PMID: 40480976
STM2457 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jun 6;16(1):5251. [Abstract]
RT-qPCR data showed m6A methylation and MAPT-paRNA expression with and without STM2457 (10 μM; 24 h) treatment in induced pluripotent stem cell (iPSC)-derived human excitatory neurons (i3Neurons).
-
Nat Commun
DHX36 binding induces RNA structurome remodeling and regulates RNA abundance via m6A reader YTHDF1. [Abstract]2024 Nov 15;15(1):9890. PMID: 39543097 -
Nat Commun
METTL3-mediated chromatin contacts promote stress granule phase separation through metabolic reprogramming during senescence. [Abstract]2024 Jun 26;15(1):5410. PMID: 38926365
STM2457 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 26;15(1):5410. [Abstract]
Incubated RAS-induced senescent cells with antibodies targeting YTHDF3 and TIAR when treated with DMSO or METTL3 inhibitor (2.5 μM STM2457) for 48 h.
-
Nat Commun
Multigenerational paternal obesity enhances the susceptibility to male subfertility in offspring via Wt1 N6-methyladenosine modification. [Abstract]2024 Feb 14;15(1):1353. PMID: 38355624
STM2457 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Feb 14;15(1):1353. [Abstract]
STM2457 (50.0 mg/kg, once a week for 5 weeks) was administered. The protein level of testicular METTL3 was measured. n = 6 mice.
-
Redox Biol
Histone lactylation-regulated METTL3 promotes ferroptosis via m6A-modification on ACSL4 in sepsis-associated lung injury. [Abstract]2024 Aug:74:103194. PMID: 38852200 -
Nucleic Acids Res
2026 Mar 19;54(6):gkag220. PMID: 41854072 -
Nucleic Acids Res
Increased PTCHD4 expression via m6A modification of PTCHD4 mRNA promotes senescent cell survival. [Abstract]2024 Jul 8;52(12):7261-7278. PMID: 38721764
STM2457 purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2024 Jul 8;52(12):7261-7278. [Abstract]
Presenescent WI-38 cells were incubated with the METTL3/METTL14 inhibitor STM2457 (2 μM) or with vehicle alone (DMSO) for 48 h.
-
J Exp Clin Cancer Res
2023 Mar 17;42(1):65. PMID: 36932427 -
Adv Sci (Weinh)
Elevated SPARC Disrupts the Intestinal Barrier Integrity in Crohn's Disease by Interacting with OTUD4 and Activating the MYD88/NF-κB Pathway. [Abstract]2025 Mar;12(11):e2409419. PMID: 39888301 -
Cell Rep Med
METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy. [Abstract]2023 Aug 15;4(8):101144. PMID: 37586322 -
Sci Adv
N6-methyladenosine modification-tuned lipid metabolism controls skin immune homeostasis via regulating neutrophil chemotaxis. [Abstract]2024 Oct 4;10(40):eadp5332. PMID: 39356764 -
Cardiovasc Res
METTL3-catalyzed m6A methylation facilitates the contribution of vascular smooth muscle cells to atherosclerosis. [Abstract]2025 May 6;121(4):568-584. PMID: 39977233 -
Cell Death Dis
2025 Dec 8;16(1):880. PMID: 41360769 -
Cell Death Dis
ADAP-METTL3 modulates the inflammatory responses of macrophages via m6A modification of Spry1. [Abstract]2025 Oct 7;16(1):708. PMID: 41057319 -
Environ Sci Technol
Ultrafine Particulate Matter Exacerbates the Risk of Delayed Neural Differentiation: Modulation Role of METTL3-Mediated m6A Modification. [Abstract]2025 Feb 18;59(6):2974-2986. PMID: 39903687 -
Cell Death Dis
TGF-β1 facilitates gallbladder carcinoma metastasis by regulating FOXA1 translation efficiency through m6A modification. [Abstract]2024 Jun 17;15(6):422. PMID: 38886389 -
Blood Cancer Discov
METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL. [Abstract]2023 May 1;4(3):228-245. PMID: 37067905 -
Cell Commun Signal
2025 Mar 8;23(1):126. PMID: 40057764 -
Cell Commun Signal
METTL3 and STAT3 form a positive feedback loop to promote cell metastasis in hepatocellular carcinoma. [Abstract]2023 May 25;21(1):121. PMID: 37231451 -
Mol Ther
Targeting O-GlcNAcylated METTL3 impedes MDS/AML progression via diminishing SRSF1 m6A modification. [Abstract]2025 Dec 3;33(12):6146-6159. PMID: 40914805 -
Phytomedicine
Reserpine, a novel N6-methyladenosine regulator, reverses Lenvatinib resistance in hepatocellular carcinoma. [Abstract]2024 Dec:135:156002. PMID: 39326134 -
J Pharm Anal
Effects and translatomics characteristics of a small-molecule inhibitor of METTL3 against non-small cell lung cancer. [Abstract]2023 Jun;13(6):625-639. PMID: 37440912 -
J Hazard Mater
Sperm Rhoa m6A modification mediates intergenerational transmission of paternally acquired hippocampal neuronal senescence and cognitive deficits after combined exposure to environmental cadmium and high-fat diet in mice. [Abstract]2023 Sep 15:458:131891. PMID: 37354721 -
Cell Death Discov
METTL3-m6A-mediated TGF-β signaling promotes Fuchs endothelial corneal dystrophy via regulating corneal endothelial-to-mesenchymal transition. [Abstract]2025 Mar 15;11(1):104. PMID: 40089501 -
J Orthop Translat
Magnesium ions facilitate osteogenic differentiation and intervertebral fusion via m6A methylation of RhoA mRNA. [Abstract]2026 Feb 18:57:101056. PMID: 41757292 -
J Transl Med
HNRNPC modulates PKM alternative splicing via m6A methylation, upregulating PKM2 expression to promote aerobic glycolysis in papillary thyroid carcinoma and drive malignant progression. [Abstract]2024 Oct 8;22(1):914. PMID: 39380010 -
Dev Cell
A microscopy-based CRISPR screening platform enables organellar functional genomics and illuminates ciliary biology. [Abstract]2025 Nov 20:S1534-5807(25)00666-5. PMID: 41270742 -
Int J Biol Macromol
17-AAG promotes the degradation of HSP90 client METTL3 to suppress MYC RNA m6A modification and expression in colorectal cancer. [Abstract]2025 Dec 3;337(Pt 1):149421. PMID: 41349747 -
EMBO J
2025 Jul;44(14):4150-4180. PMID: 40467862 -
Mol Med
Reciprocal METTL3-PAX5 regulation in maintaining B-cell identity and promoting B-cell hyperreactivity in SLE. [Abstract]2025 Jun 12;31(1):236. PMID: 40506739 -
Free Radic Biol Med
Methyltransferase-like 3 mediates m6A modification of heme oxygenase 1 mRNA to induce ferroptosis of renal tubular epithelial cells in acute kidney injury. [Abstract]2025 Mar 1:229:168-182. PMID: 39837470 -
Cell Rep
N(6)-methyladenosine modification of RNA is regulated by senataxin and E6 to control HPV replication. [Abstract]2026 Jan 9;45(1):116828. PMID: 41518615 -
Cell Rep
Hyperacute response proteins synthesized on γ-tubulin-FTO-MARK4 translation microdomains regulate cancer's acute stress response. [Abstract]2025 Jun 18;44(7):115871. PMID: 40540400 -
Cell Rep
m6A modification inhibits miRNAs' intracellular function, favoring their extracellular export for intercellular communication. [Abstract]2024 Jun 14;43(6):114369. PMID: 38878288 -
Cell Rep
Alphaherpesvirus US3 protein-mediated inhibition of the m6A mRNA methyltransferase complex. [Abstract]2022 Jul 19;40(3):111107. PMID: 35858564 -
Cell Prolif
Lin28a forms an RNA-binding complex with Igf2bp3 to regulate m6A-modified stress response genes in stress granules of muscle stem cells. [Abstract]2024 Dec;57(12):e13707. PMID: 39021312 -
Virulence
HIV-1 Vpr activates microglia by upregulating m6A modification through ubiquitin-proteasome pathway-mediated degradation of the demethylase ALKBH5. [Abstract]2026 Dec;17(1):2645908. PMID: 41824629 -
Discov Nano
The ginger-derived nanovesicles-coated albumin nanoparticles induce cell death and epigenetic regulation to treat colorectal cancer. [Abstract]2026 May 28;21(1):223. PMID: 42207394 -
Ecotoxicol Environ Saf
N6-methyladenosine facilitates arsenic-induced neoplastic phenotypes of human bronchial epithelial cells by promoting miR-106b-5p maturation. [Abstract]2024 Sep 15:283:116803. PMID: 39094460 -
Biochem Pharmacol
METTL3 regulates rifampicin-induced CYP3A4 expression by activating PXR translation and nuclear import and stabilizing CYP3A4 mRNA. [Abstract]2025 Sep:239:117016. PMID: 40466953 -
Biochem Pharmacol
STM2457 decreases m6A methylation to reduce cisplatin-induced ototoxicity via MAPK signaling. [Abstract]2025 May:235:116820. PMID: 39983847 -
Cancer Gene Ther
WTAP stabilized by USP7 contributes to enzalutamide resistance in prostate cancer via mediating AKT m6A-modification. [Abstract]2026 Mar;33(3):277-288. PMID: 41981278 -
Life Sci
Inhibition of METTL3 alleviated LPS-induced alveolar epithelial cell apoptosis and acute lung injury via restoring neprilysin expression. [Abstract]2023 Nov 15:333:122148. PMID: 37805166 -
Transl Res
2023 Sep:259:62-71. PMID: 37121538 -
-
Cells
Epitranscriptomic Regulation of Platinum Resistance via the METTL3-ADAM23 Axis in Ovarian Cancer. [Abstract]2026 Feb 4;15(3):294. PMID: 41677656 -
EMBO Rep
2025 Oct 6. PMID: 41053315 -
Mol Cancer Res
METTL3-mediated m6A modification regulates the polycomb repressive complex 1 (PRC1) components BMI1 and RNF2 in hepatocellular carcinoma cells. [Abstract]2025 Mar 3;23(3):190-201. PMID: 39625677 -
Commun Biol
m6A modification regulates cell proliferation via reprogramming the balance between glycolysis and pentose phosphate pathway. [Abstract]2025 Mar 26;8(1):496. PMID: 40140553 -
J Gastroenterol
Inhibiting METTL3 synergizes with Notch blockade to treat ESCC by targeting cancer stemness via m6A-JAG2. [Abstract]2026 Jun 11. PMID: 42274788 -
Biochim Biophys Acta Mol Basis Dis
METTL3 promotes human amniotic epithelial stem cells differentiation into insulin-producing cells by regulation of MaFA expression. [Abstract]2025 Aug;1871(6):167904. PMID: 40374016 -
Biochim Biophys Acta Mol Basis Dis
TNF-α drives bladder cancer metastasis via METTL3-mediated m6A modification to promote CLASP2/IQGAP1-dependent cytoskeleton remodeling. [Abstract]2025 Jun;1871(5):167811. PMID: 40118293 -
PLoS Pathog
Paramyxovirus matrix protein redirects METTL3 for dual regulation of viral replication and immune evasion. [Abstract]2025 Dec 1;21(12):e1013755. PMID: 41325422 -
Exp Neurol
Drugs targeting synaptic RNA m6A methylation regulate synaptic transmission and plasticity in the rat hippocampus. [Abstract]2026 Aug:402:115802. PMID: 42066972 -
Neuropharmacology
Emerging role of N6-methyladenosine (m6A) epitranscriptomic changes in adult anxiety after adolescent alcohol exposure. [Abstract]2026 Mar 1:285:110777. PMID: 41276160 -
Med Oncol
Mechanisms of astragalus polysaccharide enhancing STM2457 therapeutic efficacy in m6A-mediated OSCC treatment. [Abstract]2026 Jan 20;43(2):122. PMID: 41557107 -
Cell Signal
Gambogic acid induces ferroptosis and suppresses colorectal cancer progression by modulating the m6A modification of p62. [Abstract]2025 Nov:135:112024. PMID: 40721064 -
Cell Signal
tRNA methyltransferase DNMT2 promotes hepatocellular carcinoma progression and enhances Bortezomib resistance through inhibiting TNFSF10. [Abstract]2025 Mar:127:111533. PMID: 39617358 -
Med Oncol
STM2457 impairs the proliferation of esophageal squamous cell carcinoma by activating DNA damage response through ATM-Chk2 axis. [Abstract]2025 Feb 22;42(3):82. PMID: 39985567 -
J Inflamm Res
METTL3/IGF2BP2-Mediated m6A RNA Methylation Drives Alveolar Macrophage-Dependent Neutrophil Recruitment in Cigarette Smoke-Induced COPD. [Abstract]2025 Oct 29:18:15033-15047. PMID: 41185691 -
iScience
N6-methyladenosine modification promotes hepatocarcinogenesis through circ-CDYL-enriched and EpCAM-positive liver tumor-initiating exosomes. [Abstract]2023 Oct 13;26(10):108022. PMID: 37954137 -
Antiviral Res
Onvansertib and vilazodone inhibit SARS-CoV-2 replication via suppression of METTL3 RNA-m6A enzymatic activity. [Abstract]2026 Apr:248:106376. PMID: 41722706 -
Biochim Biophys Acta Mol Cell Res
Heat shock protein 70 regulates m6A modification in response to heat shock in esophageal squamous cell carcinoma. [Abstract]2025 Jul 24;1872(8):120027. PMID: 40714122 -
FASEB J
METTL3 and IGF2BP2 coordinately regulate FOSL1 mRNA via m6A modification, suppressing trophoblast invasion and contributing to fetal growth restriction. [Abstract]2024 Nov 30;38(22):e70154. PMID: 39565355 -
Biology (Basel)
2023 Jul 14;12(7):1004. PMID: 37508433 -
J Virol
METTL3 regulates PRRSV replication by suppressing interferon beta through autophagy-mediated IKKε degradation. [Abstract]2025 Jul 22;99(7):e0009825. PMID: 40548751 -
J Virol
The loss of hepatitis B virus receptor NTCP/SLC10A1 in human liver cancer cells is due to epigenetic silencing. [Abstract]2024 Oct 22;98(10):e0118724. PMID: 39297647 -
J Biol Chem
Epstein-Barr virus suppresses N6-Methyladenosine modification of TLR9 to promote immune evasion. [Abstract]2024 May;300(5):107226. PMID: 38537697 -
J Endocrinol Invest
METTL3 overexpression and ATF6 silencing-induced Inhibition in HAS2 expression relieves PDGF-BB stimulation-induced HA production and the proliferation of human orbital fibroblasts in graves' ophthalmopathy. [Abstract]2025 Jul 9. PMID: 40632442 -
BMC Genomics
Genome-wide analysis of lncRNA m6A methylation in the mouse cortex after repetitive mild traumatic brain injury. [Abstract]2025 May 20;26(1):509. PMID: 40394496 -
Ren Fail
DKK3 promotes renal fibrosis by increasing MFF-mediated mitochondrial dysfunction in Wnt/β-catenin pathway-dependent manner. [Abstract]2024 Dec;46(1):2343817. PMID: 38682264 -
Pathol Res Pract
METTL3 promotes ovarian cancer progression through YTHDF2-dependent degradation of GATA4. [Abstract]2025 Sep 9:275:156224. PMID: 40945198 -
Genomics
m6A-RNA epitranscriptomes regulate splicing and neuronal development in the Pacific oyster Crassostrea gigas. [Abstract]2025 Oct 13;117(6):111142. PMID: 41093079 -
Reproduction
METTL3-mediated m6A modification promotes ferroptosis in adenomyosis through GPX4 in a YTHDF1-dependent manner. [Abstract]2025 Sep 19;170(4):e250251. PMID: 40911580 -
J Leukoc Biol
2024 Oct 1;116(4):807-815. PMID: 38657004 -
J Cancer
METTL3 Inhibition Suppresses Cell Growth and Survival in Colorectal Cancer via ASNS Downregulation. [Abstract]2024 Jul 16;15(15):4853-4865. PMID: 39132158 -
Mol Biol Rep
YTHDF proteins differentially regulate a subset of m6A-modified transcripts to restrain endothelial inflammation during homeostasis. [Abstract]2026 Mar 18;53(1):510. PMID: 41848956 -
PLoS One
The METTL3 inhibitor STM2457 suppresses gastric cancer progression by modulating m6A RNA modification. [Abstract]2026 Mar 24;21(3):e0345744. PMID: 41875089 -
Biochemistry
2022 May 23;61(11):1005-1013. PMID: 35605980 -
Mol Reprod Dev
2026 May;93(5):e70106. PMID: 42112538 -
Sci Prog
Embryonic stem cell-derived small extracellular vesicles alleviate lead-induced cochlear spiral ganglion neurons injury by activating PI3 K/AKT signaling pathway. [Abstract]2025 Jul-Sep;108(3):368504251358007. PMID: 40630004 -
-
-
-
bioRxiv
2026 Mar 18:2026.03.18.712554. PMID: 41890003 -
bioRxiv
Radiation synergizes with BET inhibition to stimulate durable, systemic anti-tumor immunity in murine cancer models. [Abstract]2026 Feb 18:2026.02.16.706212. PMID: 41757027 -
Res Sq
Inhibition of N6-Methyladenosine Accumulation by Targeting METTL3 Mitigates Tau Pathology and Cognitive Decline in Alzheimer's Disease. [Abstract]2025 Dec 19:rs.3.rs-8379573. PMID: 41510223 -
-
-
-
-
Oncotarget
2025 May 8:16:291-309. PMID: 40338154 -
-
-
bioRxiv
Rewired m6A methylation of promoter antisense RNAs in Alzheimer's disease regulates global gene transcription in the 3D nucleome. [Abstract]2025 Mar 24:2025.03.22.644756. PMID: 40196645 -
bioRxiv
2025 Jan 31:2025.01.30.635805. PMID: 39975020 -
-
-
-
-
Solvente y solubilidad
DMSO : 100 mg/mL (224.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 3.33 mg/mL (7.49 mM); Clear solution; Need ultrasonic
Add each solvent one by one: 20% HP-β-CD in Saline
Solubility: 5 mg/mL (11.25 mM); Clear solution; Need ultrasonic
Add each solvent one by one: 15% Solutol HS 15 10% Cremophor EL 35% PEG400 40% Water
Solubility: 5 mg/mL (11.25 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2496 mL | 11.2478 mL | 22.4957 mL | 56.2392 mL |
| 5 mM | 0.4499 mL | 2.2496 mL | 4.4991 mL | 11.2478 mL | |
| 10 mM | 0.2250 mL | 1.1248 mL | 2.2496 mL | 5.6239 mL | |
| 15 mM | 0.1500 mL | 0.7499 mL | 1.4997 mL | 3.7493 mL | |
| 20 mM | 0.1125 mL | 0.5624 mL | 1.1248 mL | 2.8120 mL | |
| 25 mM | 0.0900 mL | 0.4499 mL | 0.8998 mL | 2.2496 mL | |
| 30 mM | 0.0750 mL | 0.3749 mL | 0.7499 mL | 1.8746 mL | |
| 40 mM | 0.0562 mL | 0.2812 mL | 0.5624 mL | 1.4060 mL | |
| 50 mM | 0.0450 mL | 0.2250 mL | 0.4499 mL | 1.1248 mL | |
| 60 mM | 0.0375 mL | 0.1875 mL | 0.3749 mL | 0.9373 mL | |
| 80 mM | 0.0281 mL | 0.1406 mL | 0.2812 mL | 0.7030 mL | |
| 100 mM | 0.0225 mL | 0.1125 mL | 0.2250 mL | 0.5624 mL |
STM2457 Related Classifications
HY-134836 Related Classifications
Powered by Bioz